China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Gets Downgrade from Wall Street Zen

China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings downgraded China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday, November 9th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Read Our Latest Analysis on China SXT Pharmaceuticals

China SXT Pharmaceuticals Stock Performance

NASDAQ SXTC opened at $3.00 on Friday. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average price of $114.33 and a 200 day moving average price of $10,872.08. China SXT Pharmaceuticals has a 52 week low of $2.71 and a 52 week high of $8,375,880.00.

About China SXT Pharmaceuticals

(Get Free Report)

China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the development, manufacture and sale of traditional Chinese medicine (TCM) products. The company produces herbal formulations intended for use in the treatment and management of various health conditions, as well as products positioned for general wellness and health maintenance. Its product portfolio includes prescription medicines, over-the-counter medicines and dietary supplements. The company’s offerings are based on traditional Chinese medicinal practices and may be provided in forms such as herbal extracts, pills and other finished formulations.

See Also

Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.